Saturday 17 October 2026
Export TCRX’s income statement to Excel — free account
TScan Therapeutics, Inc.
TCRX Healthcare Biotechnology
TScan Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.3 million, up 266.7% from fiscal 2024. In the quarter to June 2026, revenue fell 65.8%, EPS grew 17.9%, free cash flow grew 19.0% and total debt rose 1.50%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.23
0.01
−4.17%
Follow TCRX
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 1 | 3 | 3 | 2 |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 0.59 | (1.28) | 0.29 | (0.21) | (3.54) |
P/S ratio |
— | — | 2.45 | 5.18 | 3.04 | 17.80 | 120.90 | 12.57 |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | (4.38) | 7.88 | (0.28) | 0.00 | 0.75 | (5.99) |
P/Operating CF |
— | — | (1.36) | (3.65) | (2.57) | (15.76) | (12.42) | (4.06) |
P/B ratio |
— | — | 0.00 | 0.33 | 0.41 | 2.48 | 1.41 | 1.05 |
Price to Tangible BV |
— | — | 0.00 | 0.33 | 0.41 | 2.48 | 1.41 | 1.05 |
EV/Sales |
— | — | (14.23) | (10.14) | (3.39) | 10.10 | 32.94 | 1.96 |
EV/EBITDA |
— | — | 2.68 | 2.27 | 0.75 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | 2.51 | 2.11 | 0.69 | (3.46) | (0.84) | (0.15) |
EV/FCF |
— | — | 1.95 | 1.76 | 0.65 | (3.30) | (0.81) | (0.14) |
Quick Ratio |
— | 17.43 | 1.99 | 7.56 | 6.94 | 6.44 | 8.07 | 8.15 |
Current Ratio |
— | 17.69 | 2.09 | 7.76 | 7.17 | 6.51 | 8.14 | 8.41 |
Net Debt/EBITDA |
— | 2.69 | 1.09 | 3.43 | 1.42 | 1.84 | 1.97 | 0.90 |
Debt/Assets |
0.00% | 9.90% | 14.95% | 3.21% | 16.56% | 11.04% | 8.64% | 14.22% |
Debt/Equity |
— | (0.29) | (0.18) | 0.04 | 0.33 | 0.20 | 0.13 | 0.26 |
Asset Turnover |
— | 0.00 | 0.02 | 0.09 | 0.07 | 0.09 | 0.01 | 0.03 |
Operating CF/Net income |
— | 0.92 | 0.12 | 1.00 | 1.00 | 0.69 | 0.87 | 1.04 |
Capex/Depreciation |
— | (2.40) | (3.45) | (2.99) | (0.82) | (0.59) | (0.93) | (1.54) |
Interest Coverage |
— | (25.74) | (247.48) | (3,040.06) | (56.66) | (24.86) | (36.91) | (49.05) |
| — | 45.83% | 87.67% | (82.20%) | (50.90%) | (71.29%) | (65.08%) | (71.28%) | |
| — | (55.31%) | (52.72%) | (40.89%) | (34.21%) | (37.87%) | (39.64%) | (43.26%) | |
ROIC |
— | 0.00% | 0.00% | (561.31%) | (336.46%) | 0.00% | 0.00% | (2,610.99%) |
Return on Tangible Assets |
— | (32.81%) | (105.96%) | (31.15%) | (56.64%) | (51.82%) | (48.29%) | (88.14%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 1,896.50% | 443.29% | 441.96% | 418.80% | 3,812.14% | 1,105.57% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 621.29% | 136.36% | 150.37% | 125.20% | 1,075.53% | 309.81% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 47.47% | 24.81% | 33.62% | 24.74% | 339.10% | 113.38% |
Graham Net Nets |
— | — | (5.49) | 2.64 | 0.60 | 0.19 | 0.48 | 0.40 |
Graham Number |
— | — | 172.48 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | (280.02%) | (92.71%) | (160.82%) | (33.10%) | (37.83%) | (100.00%) |
Free Cash Flow Yield |
— | — | (297.80%) | (111.69%) | (172.00%) | (17.22%) | (33.68%) | (107.67%) |
Revenue per Share |
— | 0.00 | 1.18 | 0.87 | 0.56 | 0.32 | 0.03 | 0.08 |
Operating CF per Share |
— | (32.52) | (3.30) | (4.17) | (2.77) | (0.94) | (0.99) | (1.04) |
Capex per Share |
— | (3.24) | (4.63) | (0.85) | (0.18) | (0.05) | (0.03) | (0.03) |
Free Cash Flow per Share |
— | (35.76) | (7.93) | (5.03) | (2.94) | (0.98) | (1.02) | (1.08) |
Cash per Share |
— | 108.48 | 37.98 | 13.84 | 4.99 | 2.93 | 2.59 | 1.17 |
Shareholders Equity per Share |
— | (44.51) | (46.36) | 13.79 | 4.13 | 2.30 | 2.15 | 0.95 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (44.51) | (46.36) | 13.79 | 4.13 | 2.30 | 2.15 | 0.95 |
Free Cash Flow |
— | (13.77) | (7.26) | (58.62) | (70.73) | (64.50) | (114.65) | (139.73) |
Working Capital |
— | 39.98 | 19.00 | 144.31 | 106.82 | 164.42 | 256.77 | 138.51 |
Capital Expenditures |
— | (1.25) | (4.24) | (9.94) | (4.22) | (3.15) | (3.82) | (4.41) |
Net Current Asset Value |
— | (24.14) | (55.75) | 138.33 | 24.47 | 72.96 | 162.57 | 51.54 |
EV/EBIT |
— | — | 2.53 | 2.12 | 0.69 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 3.91 | 0.98 | 0.31 | 0.15 | 1.36 | 0.43 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.32 | 0.22 | 0.28 | 0.51 | 0.69 | 0.57 | 0.33 |
Cash ROIC |
— | (46.65%) | 3,063.71% | (17.86%) | (28.02%) | (17.30%) | (20.36%) | (45.36%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Payables |
— | 1.96 | 1.96 | 2.34 | 2.34 | 2.64 | 3.33 | 2.76 |
Average Assets |
— | 24.69 | 49.56 | 118.92 | 193.60 | 235.62 | 321.63 | 299.95 |
Average Common Equity |
— | (29.80) | (29.80) | 59.16 | 130.11 | 125.15 | 195.92 | 182.05 |
Columns are period end dates